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Whereas coronary angioplasty has been demonstrated to be
unnecessary and perhaps harmful for most patients after success-
ful thrombolytic treatment of acute myocardial infarction, the
clinical benefit of rescue angioplasty after failed thrombolysis
remains untested in a randomized clinical trial. However, in the
clinical judgment of many physicians it is unethical to withhold
such treatment, whereas a nearly equal number of physicians
believe that such treatment cannot be justified. A review of
reported nonrandomized data from a limited number of patients
suggests that 1) coronary angioplasty is successful in only 80% of
patients after failed thrombolysis, 2) later reocclusion rates may
Recent large scale clinical trials (1-3) evaluating coronary
angioplasty after thrombolytic intervention for acute myo-
cardial infarction have clearly demonstrated that immediate
coronary angioplasty after successful thrombolysis is unnec-
essary and is quite possibly harmful. Unfortunateiy, these
trials and others (4) have established neither a beneficial nor
a detrimental effect of coronary angioplasty after failed
thrombolysis (often referred to as rescue or salvage coronary
angioplasty) because they were not designed to address that
issue directly. In fact, to date the results of only one very
small scale randomized trial assessing the clinical utility of
rescue coronary angioplasty have been reported (5). The
potential merit of this aggressive and costly form of inter-
vention, which is of considerable public health importance
(each year, 60,000 to 100,000 patients in the United States
alone might be eligible) (6-8), remains hotly debated.
To provide a substantive answer, as opposed to the
intuitive answer currently available, the Randomized Eval-
uation of Salvage Angioplasty with Combined Utilization of
Endpoints (RESCUE) study was designed and initiated in
1990. The study will randomize 200 patients with a first
anterior myocardial infarction and demonstrated occlusion
of the infarct-related artery after thrombolytic therapy <8 h
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depend on the thrombolytic agent used, 3) left ventricular ejection
fraction is seldom improved, and 4) mortality rates after success-
ful angioplasty approximate those after successful thrombolysis
alone but mortality rates after failed angioplasty are remarkably
high.
The arguments for and against rescue angioplasty are re-
viewed, and it is concluded that results of randomized trials are
needed to replace disparate clinical opinion on whether this
potentially costly form of therapy should be widely implemented.
(J Am Coll CardioI1992;19:681-6)
from the onset of chest pain either to rescue coronary
angioplasty or to no immediate coronary angioplasty.
More than 150 academic and private centers recognized
for their excellence in interventional cardiology were ap-
proached to participate in this trial. Nearly 80% of them
declined. Many potential investigators stated, in effect, that
it is unethical to withhold treatment in this setting or that the
momentum for reperfusion would be too great to withstand
once a closed infarct-related artery was identified in the
catheterization laboratory, and investigators often cited
pressure from referring physicians. Physicians from other
centers stated that they no longer provide the routine 24-h
catheterization laboratory coverage necessary for such a
trial because of cost limitations and because coronary angio-
plasty has not been shown to be effective after thrombolytic
therapy for acute myocardial infarction.
It would seem that proponents of rescue angioplasty
might do well to recall the previously held but recently
refuted or challenged beliefs that coronary angioplasty after
successful thrombolytic therapy would improve left ventric-
ular function or decrease recurrent ischemia (1-3) and that
identification of severe stenoses by catheterization after
thrombolytic therapy might allow selective revascularization
of patients at highest risk of recurrent ischemia (9,10).
Furthermore, physicians in favor of rescue angioplasty
might be asked to account for the exceedingly high mortality
rate (25% to 40%) reported from nonrandomized studies in
patients for whom rescue angioplasty was unsuccessful
(11-15).
Proponents of the more conservative wait and see atti-
tude should be asked to remember that no moderate or large
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Table 1. Basis for Polarity of Opinion Regarding
Rescue Angioplasty
scale randomized trial of rescue angioplasty has been per-
formed to date and that the lack of efficacy of coronary
angioplasty after thrombolytic therapy demonstrated in mul-
tiple randomized trials must reasonably apply only to the
majority of patients in those trials (that is, patients with
patent vessels after thrombolytic therapy). They should also
be asked to account for the apparent marked disparity (a
two- to fourfold difference) jn survival between those with
successful and unsuccessful rescue angioplasty noted in
most reports (11-15).
The Rationale for Rescue Angioplasty
The argument for potential benefit of rescue angioplasty
is based on these facts: I) currently available intravenous
thrombolytic regimens achieve early infarct vessel patency
in only 55% to 90% of patients (1,6-8,16-18); 2) a patent
Thrombolysis in Myocardial Infarction (TIMI) (6) flow grade
III artery at immediate angiography has been shown to be an
independent predictor of improved in-hospital survival by
the Thrombolysis and Angioplasty in Myocardial Infarction
(TAMI) group (19); 3) it has been strongly suggested that
reperfusion improves rates of late postinfarction survival
compared with rates of survival after partial or no reperfu-
sion, even when reperfusion is established too late to im-
prove left ventricular function (20,21); and 4) whether early
patency of the infarct-related artery is achieved by throm-
bolysis or by rescue angioplasty, it seems to convey a
similarly favorable short- and long-term outlook (15) (Table
I).
Difficulties in making a prompt diagnosis. However, pro-
ponents of rescue angioplasty must consider the impact of
Pro-Rescue
I. Rescue angioplasty improves
early infarct artery patency rates.
2. Reperfusion with thrombolytic
therapy alone is associated with
improved short-and long-term
survival.
3. Even relatively late reperfusion
may improve infarct healing,
decrease ventricular arrhythmias
and provide a potential future
source of collateral flow.
Anti-Rescue
I. Rescue coronary angioplasty
has no proved benefit.
2. Improved thrombolytic
regimens have led to infarct-
related artery patency rates of
nearly 90%.
3. Reliable clinical markers of
successful reperfusion have not
been validated for widespread
application.
4. Spontaneous late reperfusion
may have a beneficial impact on
survival.
5. Rescue coronary angioplasty
leads to high rates of
reocclusion.
6. Patients who have had
unsuccessful rescue coronary
angioplasty have had a very
high mortality rate.
7. Rescue coronary angioplasty is
too costly and impractical.
the inherent time delay necessary with rescue angioplasty.
For instance, Sharkey et al. (22) reported an average 90-min
delay in the emergency room between patient presentation
and the administration of thrombolytic therapy in their
experience in the TIMI II trial. When one also considers the
time required to diagnose the failure of thrombolytic therapy
and the time from that diagnosis to the implementation of
rescue angioplasty, it is not unreasonable to expect an
inherent 4- to 8-h delay between the onset of chest pain and
the application of rescue angioplasty.
Prompt and accurate diagnosis of failed thrombolysis
must be an integral part of the strategy of rescue angioplasty
to minimize the delay before attempted coronary angioplasty
and to ensure that patients whose arteries have opened
during thrombolysis are not taken to the catheterization
laboratory. Unfortunately, a routine 12-lead electrocardio-
gram (ECG) and clinical symptoms cannot be relied on to
make that diagnosis. This point has been emphasized by
Califfet al. (23) from the TAMI I experience, in which vessel
patency was not achieved in 25% of patients. Even in
patients with demonstrated ST segment improvement, and
also in patients with resolution of chest pain, 16% of infarct
vessels were closed. However, it is quite likely that in the
near future bedside kits to rapidly assay myoglobin or
creatine kinase isoenzymes may be available to improve
diagnostic accuracy. It has now been clearly demonstrated
that with coronary reperfusion, myoglobin and creatine
kinase MM-III isoform peak within 30 min, compared with a
peak at 7 to 8 h without reperfusion (24). On the basis of this
difference, Ellis et al. (24) have shown that serial serum
myoglobin levels can be used to distinguish between patients
with and without reperfusion with a predictive accuracy of
88%. In addition, real time digital analysis of ST segment
shifts has also demonstrated promise in the detection of
failed reperfusion (25).
Why might late reperfusion be beneficial? Even consider-
ing improved diagnostic techniques, it is apparent that a
widespread clinical benefit from rescue angioplasty must
rely on the beneficial effect of relatively late reperfusion.
Although reperfusion within I to 1.5 h may allow for marked
recovery of left ventricular function (26), reperfusion after
3 h does not generally result in marked recovery of systolic
function (27-30). Nevertheless, a paradox between im-
proved in-hospital survival and the lack of improvement in
left ventricular function has been noted by several authors
(31). Why might late reperfusion be beneficial? At least three
reasons with some experimental or clinical foundation sup-
port the concept that late reperfusion might have a salutary
effect. First, late reperfusion has been shown to improve
infarct healing and to decrease infarct expansion in an animal
model. For instance, in the classic study by Hochmann and
Choo (32), although circumflex artery reperfusion after 2hof
occlusion in a rat modelled to no improvement in infarct size
compared with permanent ligation, an index of infarct ex-
pansion was reduced by >30% compared with permanent
coronary ligation, and nearly equaled that seen with reper-





fusion after 30 min of occlusion. These data and those of
White et al. (33) demonstrating that left ventricular end-
systolic dimension is the most important predictor of long-
term survival after myocardial infarction suggest that late
reperfusion may improve infarct healing and remodeling and
may be clinically beneficial. Second, coronary reperfusion
appears to decrease the likelihood of electrical instability
after myocardial infarction. Thus, Sager et al. (34) demon-
strated in 32 patients with left ventricular aneurysm after
myocardial infarction that ventricular tachycardia was in-
ducible in 88% of patients who did not receive thrombolytic
therapy compared with 8% of patients who did receive such
therapy (and presumably had a higher incidence of a patent
infarct artery [p = 0.008]), despite the fact that the left
ventricular ejection fraction in these two groups was similar
(30 ± 8% vs. 28 ± 9%). Furthermore, ventricular tachycar-
dia-free survival was greatly improved in patients without
compared with those with inducible ventricular tachycardia
(p = 0.02 over 24 months) (34). Thrombolytic therapy has
also been shown (35) to decrease the presence of abnormal
late potentials on the signal-averaged ECG recorded 7 to to
days after infarction. Finally, a patent coronary artery after
myocardial infarction may become important as a source for
collateral vessels in the event of stenosis progression in
contralateral vessels.
Why Might Rescue Angioplasty Be
Unnecessary?
Rescue angioplasty might not prove to be necessary or
beneficial for several reasons (Table 1). First, it is apparent
that rapid infusion or other new regimens for administering
intravenous thrombolytic therapy or new adjunctive thera-
pies might improve reperfusion and patency rates of the
infarct-related artery to the point that rescue angioplasty
might need to be considered only very infrequently (18,36).
For instance, Neuhaus et al. (18) recently reported a 91%
patency rate with a front-loaded regimen of recombinant
tissue-type plasminogen activator (rt-PA) administration.
Other groups (36-38) have also reported patency rates >80%
with front-loaded rt-PA regimens. However, given the TlMI
experience that a relatively high dose infusion of rt-PA is
associated with a 1.3% incidence rate of intracranial hemor-
rhage, one must be cautious in accepting the widespread
application of front-loaded rt-PA regimens without a dem-
onstration of their safety in a large number of patients.
Second, it is quite possible that delayed thrombolysis-
induced reperfusion may be sufficient to achieve a nearly
optimal rate of in-hospital patient survival. The recently
reported 85% rate of infarct-related artery patency at 24 h
after administration of intravenous streptokinase compared
with the 64% patency rate at 90 min reported by the
Pro-urokinase in Myocardial Infarction (PRIMI) Trial (39)
suggests that "catch up" reperfusion may be achieved by
agents that have suboptimal 60- to 90-min patency rates. It
appears that patency may be achieved after 3 h of treatment
with streptokinase in nearly 75% of infarct-related arteries
(40). The potential importance of this finding is highlighted
by the lack of mortality reduction achieved by rt-PA in the
International t-PA/SK (streptokinase) mortality trial (mortal-
ity with t-PA = 8.9%; mortality with streptokinase = 8.5%,
p = NS) (41). Because most patients are treated after the
window of opportunity for retrieving left ventricular systolic
function (probably 2 to 3 h in humans, except possibly in the
presence of developed collateral flow or intermittent occlu-
sion), improved hospital survival may not depend on early
reperfusion (42). There may be no need to attempt to speed
reperfusion with rescue coronary angioplasty if 20% to 60%
of patients with a closed artery 90 min after treatment have
later reperfusion. This argument may apply particularly to
patients treated with streptokinase and also may explain why
mortality differences between rt-PA and streptokinase-
treated patients were not observed in the International
t-PA/SK or International Studies ofinfarct Survival (ISIS)-3
trials (41; ISIS-3, unpublished observations, 40th Annual
Scientific Session, American College of Cardiology, Atlanta,
Georgia, March 1991). Of course, the impact of the timing
and method of administration of heparin in these studies
clouded the meaning and interpretation of the results and
served as the impetus for the organization of further large
scale studies of the relative efficacy of these two throm-
bolytic agents. It should be recalled, however, that nearly
one-half of hospitalized patients who die do so within the 1st
6 h of treatment (42), implying that this may be a particularly
critical time for revascularization.
Third, the potential harm from attempted but unsuccess-
ful rescue angioplasty may outweigh any benefit from suc-
cessful rescue coronary angioplasty. Although the exact
cause is uncertain, failed rescue coronary angioplasty has
been associated with in-hospital mortality rates as high as
39% (15), which is particularly worrisome because these
rates appear to be much higher than expected from the
patients' presenting clinical characteristics. For example, of
23 patients from the Thrombolysis and Angioplasty in Myo-
cardial Infarction (TAMI) Study Group with failed rescue
angioplasty (mean ejection fraction = 48%) (15), 9 (39%)
died, a percent much higher than the 4% to 6% expected
from the prethrombolytic therapy era for patients with the
same ejection fraction (43).
Fourth, even when rescue angioplasty is successful, it
may neither improve the survival rate nor decrease the
incidence of congestive heart failure. The results of nonran-
domized reports of rescue angioplasty will be considered in
the following section.
Finally, rescue angioplasty may not be worth the cost
associated with its application in this era in which necessary
limitations of resources have begun to impose constraints on
the application of "high tech" medicine. Even if rescue
angioplasty can be shown to have modest benefit, who
should judge-ethicists, politicians or physicians-if the
benefit outweighs the increased cost of diagnostic testing,
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Table 2. Meta-Analysis of Reported Results of Rescue Coronary Angioplasty
First Author Thrombolytic Success Reocclusion Mortality
(Ref. no.) No.ofPts Regimen (%) (%) IlEF (%)
Topol (I) 86 rt-PA 73 29 -I 10.4
Califf (4) 15 rt-PA 87 15 +1 NR
25 UK 84 12 +1 NR
12 rt-PA + UK 92 0 +2 NR
Belenkie (5) 16 SK 81 NR +2 6.7
Fung (14) 13 SK 92 16 +10 7.6
Topol (17) 22 rt-PA + UK 86 3 +5 0
Grines (44) 12 rt-PA + SK 100 8 NR NR
Holmes (45) 34 SK 71 NR -II II
Grines (46) 10 rt-PA + SK 90 12 +5 10
O'Connor (47) 90 SK 89 14 -I 17
Bairn (48) 37 rt-PA 92 26 NR 5.4
Whitlow (49) 26 rt-PA 81 29 -2 NR
18 UK 89 25 +1 NR
Ellis (this series) 109 rt-PA 79 20 +1 10.1
5 rt-PA + UK 80 20 +2 20
59 SK 76 18 +4 10.2
Pooled SK, UK or 308* 260/308 (84%)t 31/223 (14%) -I 11.2
combination
Pooled rt-PA only 2m 191/252 (76%)t 38/157 (24%) -I 9.5
Total 560** 451/560 (80%) 69/380 (18%) -I 10.6
*Five patients included in both the series of Topol et al. (17) and this series are counted separately; tp = 0.01;
*21 patients included in both the series of Califf et al. (4) and this series are counted separately; IlEF = the change
in left ventricular ejection fraction from baseline to the measurement before hospital discharge; NR = not reported;
Pts = patients; Ref. = reference; rt-PA = recombinant tissue-type plasminogen activator; SK = streptokinase; UK
= urokinase.
rapid patient transportation and catheterization laboratory
material and personnel required for widespread implemen-
tation of such a strategy?
Reports of Randomized and Nonrandomized
Trials of Rescue Angioplasty
A review of the published data on rescue angioplasty,
even allowing for an extension of our own series (11), which
now numbers 172 patients, finds that data from only 560
patients have been reported in any detail (Table 2). Almost
all individual series report data from < 100 patients.
In the single reported randomized trial of rescue coronary
angioplasty, Belenkie et al. (5) randomized 28 patients
presenting 3 to 6 h after symptom onset. Angioplasty was
performed successfully in 13 of 16 attempts, and was asso-
ciated with a somewhat lower in-hospital mortality rate than
was no coronary angioplasty (7% vs. 33%, p = 0.13), but
there was no difference between patients with and without
angioplasty in left ventricular systolic performance at follow-
up.
Overall success rates in achieving infarct-related artery
patency range from 71% to 92%. In general, there has been
little beneficial effect on the recovery of left ventricular
function by the time of hospital discharge. However, pa-
tients with successful coronary angioplasty have had a
considerably lower mortality rate than have patients with
unsuccessful coronary angioplasty (11-14). Reocclusion af-
ter successful angioplasty has been reported in up to 29% of
patients (I), but reocclusion rates appear to be considerably
lower when long-acting, nonfibrin-specific agents are used
(4,15,17).
Origins of Biases
There are several potential sources of bias regarding the
use of rescue angioplasty. First, because an individual
physician or institution would be unlikely to have extensive
experience with rescue angioplasty, perspective on the effi-
cacy of rescue angioplasty might be colored by anecdotal
and, thus, possibly nonrepresentative, experience. Second,
some biases may originate in the extrapolation of results
from other interventions to the expected results of rescue
angioplasty. For instance, the demonstration that a widely
patent infarct-related artery after thrombolytic therapy por-
tends improved survival might lead one to conclude that an
attempt to open an artery that is closed after thrombolysis
would be warranted. This conclusion does not take into
account the fact that rescue angioplasty is not always
successful, and that the attempt to restore patency of the
infarct-related artery may itself have detrimental effects
(15,43). Similarly, one might conclude that the reocclusion
rate after rescue angioplasty is high (20% to 30%) on the
basis of an early report (I) on rescue angioplasty after the





administration of intravenous rt-PA, However, the more
recent reports of the TAMI II (17), TAMI V (4) and
Kentucky Acute Myocardial Infarction Trial (KAMIT) (45)
studies suggest that the incidence rate of reocclusion may be
considerably decreased by the use or concomitant adminis-
tration of longer-acting, nonfibrin-specific thrombolytic
agents.
Third, some biases may originate from a misunderstand-
ing of the results of reported trials, For instance, some
physicians have apparently interpreted the results of the
TAMI I (1) and TIMI IIA (2) trials to mean that rescue
angioplasty is unnecessary, In fact, the thrust of both of
these trials was to determine whether angioplasty was
needed after successful thrombolysis, not whether it was
needed after unsuccessful thrombolysis. Fourth, outside
pressures, such as the desire of the patient and family to do
everything possible that might be beneficial and the physi-
cian's desires for personal satisfaction and perhaps even
monetary gain, might also instill biases in favor of the
performance of rescue angioplasty. Finally, a consideration
of the cost of rescue angioplasty, particularly from the public
health sector, might suggest that rescue angioplasty should
not be performed. However, if rescue angioplasty could be
shown to improve patient survival and physical capacity, the
overall burden of cost to society might be lessened.
Conclusions
Available data are inadequate to allow scientific judgment
of whether attempts at rescue angioplasty are justified.
Whether beneficial or detrimental, routine application of this
strategy would be highly expensive. The need for a random-
ized trial to determine the usefulness of rescue angioplasty
appears to be great and is highlighted by the strongly held,
yet diametrically opposed, views of many potential investi-
gators who declined to participate in the multicenter RES-
CUE Trial. It is hoped that such polarization of opinion will
heighten interest rather than impede the process of this much
needed clinical trial.
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